Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Christian Schultheis (NPI 1932153822)

Field	Value
Entity Type	Individual
Organization	Christian Schultheis
Address	411 Laurel St Ste A300
City	Des Moines
State	IA
ZIP	50314
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 22, 2006

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

This provider reports $1.5M in total Medicare revenue and has no Medicaid billing on file, making their publicly visible payer mix effectively single-payer with Medicare as the dominant revenue source. The absence of any Medicaid claims on file suggests Medicare policy and utilization trends will disproportionately affect cash flow and strategic considerations for this practice.

Revenue is highly concentrated in three oncology biologic codes: J9271 ($653.6K, 44.9% of Medicare revenue), J9144 ($225.7K, 15.5%), and J9299 ($136.8K, 9.4%), and the precomputed top‑3 share equals 69.9% of total Medicare revenue. This concentration indicates the practice’s top-line Medicare performance is driven primarily by high-cost infusion drugs rather than diversified ancillary or primary-care services.

The code mix and descriptions point to an oncology infusion practice centered on immune and monoclonal antibody therapies: primary billing for pembrolizumab (J9271), daratumumab (J9144), and nivolumab (J9299) alongside chemotherapy administration codes (96413, 96365, 96367) and supportive agents such as pegfilgrastim (J2506) and denosumab (J0897). Together these codes are consistent with an outpatient infusion/service-line that manages systemic cancer therapy and associated supportive care.

Despite very large dollar shares from high-cost drugs, this provider is not a national outlier for those individual drug codes: J9271 ranks #671 of 1841 providers (63th percentile; typical, unremarkable volume), J9144 ranks #433 of 615 (28th percentile; typical, unremarkable volume), and J9299 ranks #438 of 505 (13th percentile; typical, unremarkable volume). In other words, the provider bills substantial revenue on these agents but sits within the middle-to-lower range of national peers by volume for each drug rather than being a dominant national supplier.

Evaluation-and-management coding is a notable strength: 99214 (661 claims) is at the 94th percentile (notably above typical national volume), 99213 (535 claims) is at the 95th percentile (notably above typical national volume), and 99215 (323 claims) is at the 97th percentile (notably above typical national volume). This pattern indicates high ambulatory visit throughput and above-typical visit complexity for outpatient management, consistent with ongoing oncology follow-up and care coordination.

Supportive and ancillary services are also concentrated in outpatient workflows: lab panels and phlebotomy codes such as 80053 (895 claims, 93th percentile) and 85025 (1K claims, 93th percentile), plus 36415 (753 claims, 94th percentile), signal routine on-site laboratory monitoring, while chemotherapy administration (96413 at the 81th percentile) further confirms infusion-centered operations. These ancillary volumes suggest bundled patient encounters where infusion, labs, and E/M visits are co-located.

The provider’s NPI was enumerated on 2006-05-22 (~20 years ago), indicating long-tenured Medicare participation and operational continuity that may support stable referral relationships and established infusion workflows. Long tenure combined with a high concentration in advanced immuno-oncology agents suggests an experienced oncology practice that has pivoted toward modern biologic treatments.

Given that 69.9% of Medicare revenue comes from the top three drug codes, this practice has concentrated exposure to utilization and reimbursement shifts for specific high-cost oncology biologics; coupled with no Medicaid billing on file, policy or formulary changes in Medicare would have outsized impact compared with changes in other payers. Analysts should monitor Medicare reimbursement rules and biosimilar adoption for pembrolizumab, daratumumab, and nivolumab to assess near-term revenue sensitivity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

66 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,200	$40	$653.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,940	$40	$225.7K
J9299	Injection, nivolumab, 1 mg	6,840	$20	$136.8K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,300	$40	$82.8K
J0897	Injection, denosumab, 1 mg	4,440	$20	$79.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	660	$90	$58.8K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	320	$130	$41.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	350	$90	$32.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	540	$60	$32.6K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	180	$70	$12.8K

Showing 1–10 of 66

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 66 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Christian Schultheis — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

66 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	17	30	17,200	$40	$902.3K
J9299	7	10	18,700	$20	$527.6K
J9144	8	10	9,900	$40	$476.8K
J1569	7	10	2,680	$40	$133.6K
J0897	46	190	1,920	$20	$74.1K
J2506	16	20	440	$80	$38.9K
96413	22	80	210	$90	$24K
J9217	53	50	140	$130	$23.4K
J0185	8	20	6,890	$1	$14.5K
99214	283	4,690	100	$70	$14.4K

Showing 1–10 of 66

Related Providers

Other providers that share a Tax Identification Number (TIN) with Christian Schultheis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
State University Of Iowa	IA	Family Medicine Physician	$0	$103.8M
State University Of Iowa	IA	General Acute Care Hospital	$0	$90.4M
Catholic Health Initiatives-iowa Corp	IA	General Acute Care Hospital	$0	$26.4M
State University Of Iowa	IA	Dentist	$0	$25.8M
Greater Regional Medical Center	IA	Critical Access Hospital	$0	$10M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Catholic Health Initiatives-iowa Corp	IA	Clinical Medical Laboratory	$0	$8M
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0

Nearby Providers

Other providers in the same ZIP code as Christian Schultheis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Broadlawns Medical Center	IA	General Acute Care Hospital	$0	$112.9M
Des Moines Independent Community School District	IA	Local Education Agency (LEA)	$0	$22.8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$14.1M
Broadlawns Medical Center	IA	Community/Behavioral Health Agency	$0	$13.2M
Mercy Clinics Inc	IA	Pediatric Adolescent Medicine Physician	$0	$10.7M
Des Moines River Physicians, LLC	IA	Emergency Medicine Physician	$0	$8.1M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$7.9M
Vita Health Services	IA	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$7.5M
House Of Mercy	IA	Substance Abuse Rehabilitation Facility	$0	$7.4M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$7.2M

Christian Schultheis — Billing Profile & Reimbursement Data

Sign up for Christian Schultheis — Billing Profile & Reimbursement Data policy alerts

Christian Schultheis — Billing Profile & Reimbursement Data

Sign up for Christian Schultheis — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References